• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加勒比地区成年乳腺癌和卵巢癌患者致病变异的基因测序

Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.

作者信息

George Sophia H L, Donenberg Talia, Alexis Cheryl, DeGennaro Vincent, Dyer Hedda, Yin Sook, Ali Jameel, Butler Raleigh, Chin Sheray N, Curling DuVaughn, Lowe Dwight, Lunn John, Turnquest Theodore, Wharfe Gilian, Cerbon Danielle, Barreto-Coelho Priscila, Schlumbrecht Matthew P, Akbari Mohammad R, Narod Steven A, Hurley Judith E

机构信息

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami, Miami, Florida.

Sylvester Comprehensive Cancer Center, Miami, Florida.

出版信息

JAMA Netw Open. 2021 Mar 1;4(3):e210307. doi: 10.1001/jamanetworkopen.2021.0307.

DOI:10.1001/jamanetworkopen.2021.0307
PMID:33646313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7921902/
Abstract

IMPORTANCE

Rates of breast and ovarian cancer are high in the Caribbean; however, to date, few published data quantify the prevalence of inherited cancer in the Caribbean population.

OBJECTIVE

To determine whether deleterious variants in genes that characterize the hereditary breast and ovarian cancer syndrome are associated with the development of breast and ovarian cancer in the English- and Creole-speaking Caribbean populations.

DESIGN, SETTING, AND PARTICIPANTS: This multisite genetic association study used data from germline genetic test results between June 2010 and June 2018 in the Bahamas, Cayman Islands, Barbados, Dominica, Jamaica, Haiti, and Trinidad and Tobago. Next-generation sequencing on a panel of 30 genes and multiplex ligation-dependent probe amplification (BRCA1 and BRCA2) were performed. Medical records were reviewed at time of study enrollment. Women and men diagnosed with breast and ovarian cancer with at least 1 grandparent born in the participating study sites were included; 1018 individuals were eligible and consented to participate in this study. Data were analyzed from November 4, 2019, to May 6, 2020.

EXPOSURES

Breast and/or ovarian cancer diagnosis.

MAIN OUTCOMES AND MEASURES

Rate of inherited breast and ovarian cancer syndrome and spectrum and types of variants.

RESULTS

Of 1018 participants, 999 (98.1%) had breast cancer (mean [SD] age, 46.6 [10.8] years) and 21 (2.1%) had ovarian cancer (mean [SD] age, 47.6 [13.5] years). Three individuals declined to have their results reported. A total of 144 of 1015 (14.2%) had a pathogenic or likely pathogenic (P/LP) variant in a hereditary breast and ovarian cancer syndrome gene. A total of 64% of variant carriers had P/LP variant in BRCA1, 23% in BRCA2, 9% in PALB2 and 4% in RAD51C, CHEK2, ATM, STK11 and NBN. The mean (SD) age of variant carriers was 40.7 (9.2) compared with 47.5 (10.7) years in noncarriers. Individuals in the Bahamas had the highest proportion of hereditary breast and ovarian cancer (23%), followed by Barbados (17.9%), Trinidad (12%), Dominica (8.8%), Haiti (6.7%), Cayman Islands (6.3%), and Jamaica (4.9%). In Caribbean-born women and men with breast cancer, having a first- or second-degree family member with breast cancer was associated with having any BRCA1 or BRCA2 germline variant (odds ratio, 1.58; 95% CI, 1.24-2.01; P < .001). A BRCA1 vs BRCA2 variant was more strongly associated with triple negative breast cancer (odds ratio, 6.33; 95% CI, 2.05-19.54; P = .001).

CONCLUSIONS AND RELEVANCE

In this study, among Caribbean-born individuals with breast and ovarian cancer, 1 in 7 had hereditary breast and ovarian cancer. The proportion of hereditary breast and ovarian cancer varied by island and ranged from 23% in the Bahamas to 4.9% in Jamaica. Each island had a distinctive set of variants.

摘要

重要性

加勒比地区乳腺癌和卵巢癌的发病率很高;然而,迄今为止,很少有已发表的数据能量化加勒比人群中遗传性癌症的患病率。

目的

确定在讲英语和克里奥尔语的加勒比人群中,遗传性乳腺癌和卵巢癌综合征特征基因中的有害变异是否与乳腺癌和卵巢癌的发生有关。

设计、地点和参与者:这项多中心基因关联研究使用了2010年6月至2018年6月在巴哈马、开曼群岛、巴巴多斯、多米尼克、牙买加、海地以及特立尼达和多巴哥的种系基因检测结果数据。对一组30个基因进行了下一代测序,并进行了多重连接依赖探针扩增(针对BRCA1和BRCA2)。在研究入组时查阅了医疗记录。纳入了至少有一位祖父母出生在参与研究地点且被诊断患有乳腺癌和卵巢癌的女性和男性;1018人符合条件并同意参与本研究。数据于2019年11月4日至2020年5月6日进行分析。

暴露因素

乳腺癌和/或卵巢癌诊断。

主要结局和指标

遗传性乳腺癌和卵巢癌综合征的发生率以及变异的谱系和类型。

结果

在1018名参与者中,999人(98.1%)患有乳腺癌(平均[标准差]年龄为46.6[10.8]岁),21人(2.1%)患有卵巢癌(平均[标准差]年龄为47.6[13.5]岁)。3人拒绝报告其结果。在1015人中,共有144人(14.2%)在遗传性乳腺癌和卵巢癌综合征基因中存在致病性或可能致病性(P/LP)变异。共有64%的变异携带者在BRCA1基因中有P/LP变异,23%在BRCA2基因中,9%在PALB2基因中,4%在RAD51C、CHEK2、ATM、STK11和NBN基因中。变异携带者的平均(标准差)年龄为40.7(9.2)岁,而非携带者为47.5(10.7)岁。巴哈马的遗传性乳腺癌和卵巢癌比例最高(23%),其次是巴巴多斯(17.9%)、特立尼达(12%)、多米尼克(8.8%)、海地(6.7%)、开曼群岛(6.3%)和牙买加(4.9%)。在出生于加勒比地区且患有乳腺癌的女性和男性中,有一级或二级亲属患有乳腺癌与存在任何BRCA1或BRCA2种系变异相关(比值比,1.58;95%置信区间,1.24 - 2.01;P <.001)。BRCA1变异与三阴性乳腺癌的关联更强(比值比,6.33;95%置信区间,2.05 - 19.54;P = 0.001)。

结论与意义

在本研究中,在出生于加勒比地区且患有乳腺癌和卵巢癌的个体中,七分之一患有遗传性乳腺癌和卵巢癌。遗传性乳腺癌和卵巢癌的比例因岛屿而异,从巴哈马的23%到牙买加的4.9%不等。每个岛屿都有一组独特的变异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30d2/7921902/2e9f214685e6/jamanetwopen-e210307-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30d2/7921902/2e9f214685e6/jamanetwopen-e210307-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30d2/7921902/2e9f214685e6/jamanetwopen-e210307-g001.jpg

相似文献

1
Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.加勒比地区成年乳腺癌和卵巢癌患者致病变异的基因测序
JAMA Netw Open. 2021 Mar 1;4(3):e210307. doi: 10.1001/jamanetworkopen.2021.0307.
2
Reproductive Risk Factor Patterns in Caribbean Women With Breast Cancer Across 4 Generations.加勒比海地区乳腺癌患者跨四代的生殖风险因素模式。
JAMA Netw Open. 2024 Oct 1;7(10):e2438091. doi: 10.1001/jamanetworkopen.2024.38091.
3
The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.BRCA1/2 阴性、高风险、遗传性乳腺癌和/或卵巢癌患者中致病性变异的鉴定:FANCM 致病性变异的高频率。
Int J Cancer. 2019 Jun 1;144(11):2683-2694. doi: 10.1002/ijc.31992. Epub 2019 Jan 11.
4
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.在常规诊断环境中对 5589 名 BRCA1/2 阴性乳腺癌指数患者进行基因面板检测:德国遗传性乳腺癌和卵巢癌联合会的研究结果。
Cancer Med. 2018 Apr;7(4):1349-1358. doi: 10.1002/cam4.1376. Epub 2018 Mar 9.
5
Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.遗传性乳腺癌和卵巢癌的跨学科风险咨询:来自专门中心的真实世界数据。
Arch Gynecol Obstet. 2023 May;307(5):1585-1592. doi: 10.1007/s00404-022-06819-3. Epub 2022 Oct 28.
6
Screening Familial Risk for Hereditary Breast and Ovarian Cancer.筛查遗传性乳腺癌和卵巢癌的家族风险。
JAMA Netw Open. 2024 Sep 3;7(9):e2435901. doi: 10.1001/jamanetworkopen.2024.35901.
7
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.女性 BRCA1/2、PALB2、CHEK2 和 ATM 携带者的癌症风险管理。
Breast Cancer Res Treat. 2020 Jul;182(2):421-428. doi: 10.1007/s10549-020-05699-y. Epub 2020 May 22.
8
Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.与遗传性乳腺癌和卵巢癌综合征相关的DNA修复基因中的种系变异:巴西人群中21基因检测板的分析
BMC Med Genomics. 2020 Feb 10;13(1):21. doi: 10.1186/s12920-019-0652-y.
9
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.哥伦比亚遗传性乳腺癌和卵巢癌的多基因检测研究
Fam Cancer. 2018 Jan;17(1):23-30. doi: 10.1007/s10689-017-0004-z.
10
Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.通过下一代测序技术对疑似遗传性乳腺癌和卵巢癌(HBOC)的土耳其卵巢癌患者的种系突变变体进行检测。
Pathol Res Pract. 2024 Feb;254:155075. doi: 10.1016/j.prp.2023.155075. Epub 2024 Jan 2.

引用本文的文献

1
Genetic screening of FFPE breast cancer biopsies for the -185delAG mutation in Trinidad and Tobago.特立尼达和多巴哥对福尔马林固定石蜡包埋乳腺癌活检组织进行-185delAG突变的基因筛查。
Rev Panam Salud Publica. 2025 May 20;49:e52. doi: 10.26633/RPSP.2025.52. eCollection 2025.
2
Serine/threonine kinase 11 (STK11) associated adnexal tumors: from biology to therapeutic impact.丝氨酸/苏氨酸激酶11(STK11)相关附件肿瘤:从生物学特性到治疗意义
Hum Genomics. 2025 Mar 18;19(1):28. doi: 10.1186/s40246-025-00741-w.
3
Homologous recombination deficiency in ovarian high-grade serous carcinoma by self-reported race.

本文引用的文献

1
Lynch Syndrome-Associated Variants and Cancer Rates in an Ancestrally Diverse Biobank.一个具有种族多样性的生物样本库中与林奇综合征相关的变异和癌症发病率
JCO Precis Oncol. 2020 Nov 23;4. doi: 10.1200/PO.20.00290. eCollection 2020.
2
Association of RAD51C germline mutations with breast cancer among Bahamians.RAD51C 种系突变与巴哈马人群乳腺癌的相关性。
Breast Cancer Res Treat. 2020 Nov;184(2):649-651. doi: 10.1007/s10549-020-05872-3. Epub 2020 Aug 18.
3
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
根据自我报告的种族分析卵巢高级别浆液性癌中的同源重组缺陷
medRxiv. 2025 Jan 28:2025.01.21.25320918. doi: 10.1101/2025.01.21.25320918.
4
Reproductive Risk Factor Patterns in Caribbean Women With Breast Cancer Across 4 Generations.加勒比海地区乳腺癌患者跨四代的生殖风险因素模式。
JAMA Netw Open. 2024 Oct 1;7(10):e2438091. doi: 10.1001/jamanetworkopen.2024.38091.
5
A global perspective on the ethnic-specific variation and its implication in clinical application.关于种族特异性变异及其在临床应用中的意义的全球视角。
J Natl Cancer Cent. 2022 Dec 15;3(1):14-20. doi: 10.1016/j.jncc.2022.12.001. eCollection 2023 Mar.
6
Global, regional, and national burden of ovarian cancer among young women during 1990-2019.1990年至2019年间年轻女性卵巢癌的全球、区域和国家负担。
Eur J Cancer Prev. 2025 Jan 1;34(1):1-10. doi: 10.1097/CEJ.0000000000000899. Epub 2024 Jun 4.
7
Prognostic factors and overall survival of breast cancer in Benin: a hospital-based study.贝宁乳腺癌的预后因素和总生存率:一项基于医院的研究。
BMC Womens Health. 2024 May 18;24(1):295. doi: 10.1186/s12905-024-03114-y.
8
Increasing diversity of functional genetics studies to advance biological discovery and human health.增加功能遗传学研究的多样性,以促进生物学发现和人类健康。
Am J Hum Genet. 2023 Dec 7;110(12):1996-2002. doi: 10.1016/j.ajhg.2023.10.012. Epub 2023 Nov 22.
9
Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer.评估 ctDNA 在检测浆液性卵巢癌患者残留癌和预测复发中的效用。
Int J Mol Sci. 2023 Sep 21;24(18):14388. doi: 10.3390/ijms241814388.
10
Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer.胚系致病性变异与卵巢上皮癌患者的家族遗传咨询。
JCO Precis Oncol. 2023 Sep;7:e2300137. doi: 10.1200/PO.23.00137.
《NCCN 肿瘤学临床实践指南:乳腺癌》第 3.2020 版
J Natl Compr Canc Netw. 2020 Apr;18(4):452-478. doi: 10.6004/jnccn.2020.0016.
4
High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer.巴巴多斯女性乳腺癌中三阴性乳腺癌高发且预后不良的因素。
Cancer. 2020 May 15;126(10):2217-2224. doi: 10.1002/cncr.32771. Epub 2020 Mar 10.
5
Emerging Opportunity of Cascade Genetic Testing for Population-Wide Cancer Prevention and Control.级联基因检测在全人群癌症预防与控制中的新机遇
J Clin Oncol. 2020 May 1;38(13):1371-1374. doi: 10.1200/JCO.20.00140. Epub 2020 Feb 25.
6
Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.基于诊断后癌症基因检测的级联分析:一种替代基于人群的筛查方法。
J Clin Oncol. 2020 May 1;38(13):1398-1408. doi: 10.1200/JCO.19.02010. Epub 2020 Jan 10.
7
Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.外显子组测序揭示了一个多样化的基于人群的生物库中 BRCA1 和 BRCA2 种系变异的高流行率。
Genome Med. 2019 Dec 31;12(1):2. doi: 10.1186/s13073-019-0691-1.
8
Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon.乌干达和喀麦隆女性乳腺癌易感基因遗传突变的流行情况。
Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):359-367. doi: 10.1158/1055-9965.EPI-19-0506. Epub 2019 Dec 23.
9
Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families.与生殖系致病性变异相关的癌症风险:一项对524个家庭的国际研究。
J Clin Oncol. 2020 Mar 1;38(7):674-685. doi: 10.1200/JCO.19.01907. Epub 2019 Dec 16.
10
Pressing Need to Dig Deeper Into Female Cancer Health Disparities.迫切需要更深入地探究女性癌症健康差异。
J Clin Oncol. 2019 Dec 10;37(35):3464-3465. doi: 10.1200/JCO.19.01720. Epub 2019 Oct 2.